Got story updates? Submit your updates here. ›
Sanara MedTech’s innovative surgical products aim to improve clinical outcomes and reduce healthcare costs.Fort Worth Today
Sanara MedTech Inc., a medical technology company focused on developing and commercializing transformative surgical technologies, announced it will report its first quarter 2026 financial results on Tuesday, May 12, 2026 before the U.S. financial markets open. The company will host a conference call and webcast on the same day at 8:00 a.m. Eastern Time to discuss the quarterly results and hold a Q&A session.
Why it matters
As a publicly traded medical technology company, Sanara’s quarterly earnings reports provide insight into the performance and growth of its surgical product portfolio, which includes advanced biologic solutions and tissue repair grafts. The company’s ability to drive innovation and commercialize new technologies is closely watched by investors and the broader surgical market.
The details
Sanara will report its Q1 2026 financial results on May 12, 2026 before markets open. The company will then host a conference call and webcast at 8:00 a.m. Eastern Time the same day to discuss the quarterly results and take questions from analysts and investors. A replay of the call will be available for approximately two weeks following the live event.
Sanara will report Q1 2026 financial results on May 12, 2026 before U.S. markets open.The company will host a conference call and webcast on May 12, 2026 at 8:00 a.m. Eastern Time.A replay of the conference call will be available through May 26, 2026.
The players
Sanara MedTech Inc.
A medical technology company focused on developing and commercializing transformative surgical technologies to improve clinical outcomes and reduce healthcare costs.
Got photos? Submit your photos here. ›
What’s next
Investors will be able to access the live webcast of Sanara’s conference call by clicking the link provided on the company’s investor relations website.
The takeaway
Sanara’s upcoming earnings report will provide insight into the performance and growth of its innovative surgical product portfolio, which is closely watched by investors as the company continues to drive innovation in the medical technology space.